Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corporation    EW

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
83.89(c) 83.88(c) 84.47(c) 83.65(c) 85.76(c) Last
3 948 429 2 529 072 1 500 478 1 697 299 2 292 131 Volume
-1.61% -0.01% +0.70% -0.97% +2.52% Change
More quotes
Financials (USD)
Sales 2020 4 426 M - -
Net income 2020 829 M - -
Net cash position 2020 874 M - -
P/E ratio 2020 63,9x
Yield 2020 -
Sales 2021 5 091 M - -
Net income 2021 1 301 M - -
Net cash position 2021 1 637 M - -
P/E ratio 2021 41,3x
Yield 2021 -
Capitalization 53 450 M 53 450 M -
EV / Sales 2020 11,9x
EV / Sales 2021 10,2x
Nbr of Employees 13 900
Free-Float 97,4%
More Financials
Company
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - hemodynamic monitoring systems (61.4%); - heart valves and surgery products (20.4%); - other (18.1%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the... 
More about the company
Notations Surperformance© of Edwards Lifesciences Corporation
Trading Rating : Investor Rating :
More Ratings
All news about EDWARDS LIFESCIENCES CORPORATION
10/26EDWARDS LIFESCIENCES : Management's Discussion and Analysis of Financial Conditi..
AQ
10/23EDWARDS LIFESCIENCES : Reports Third Quarter Results
AQ
10/22EDWARDS LIFESCIENCES CORP : Results of Operations and Financial Condition, Finan..
AQ
10/21EDWARDS LIFESCIENCES : 3Q Earnings Snapshot
AQ
10/21EDWARDS LIFESCIENCES : Reports Third Quarter Results
PR
10/16EDWARDS LIFESCIENCES CORPORATION : quaterly earnings release
10/15MEDTRONIC : Launches Head-to-Head TAVR Study Comparing the Evolut TAVR Platform ..
AQ
10/09EDWARDS LIFESCIENCES : to Host Earnings Conference Call on October 21, 2020
AQ
10/07EDWARDS LIFESCIENCES : To Host Earnings Conference Call On October 21, 2020
PR
10/01ACTAVIS STRIKES AGAIN : Edwards Lifesciences Find Success In Second High Court H..
AQ
08/10EDWARDS LIFESCIENCES : Northwestern University and Edwards Lifesciences Catastro..
AQ
07/27EDWARDS LIFESCIENCES : Management's Discussion and Analysis of Financial Conditi..
AQ
07/23EDWARDS LIFESCIENCES CORP : Results of Operations and Financial Condition, Finan..
AQ
07/23EDWARDS LIFESCIENCES : 2Q Earnings Snapshot
AQ
07/23EDWARDS LIFESCIENCES : Reports Second Quarter Results
PR
More news
News in other languages on EDWARDS LIFESCIENCES CORPORATION
10/16EDWARDS LIFESCIENCES CORPORATION : publication des résultats trimestriels
10/16EDWARDS LIFESCIENCES CORPORATION : Veröffentlichung des Quartalsergebnisses
07/20EDWARDS LIFESCIENCES CORPORATION : publication des résultats semestriels
07/20EDWARDS LIFESCIENCES CORPORATION : Veröffentlichung des Halbjahresergebnisses
04/20EDWARDS LIFESCIENCES CORPORATION : publication des résultats trimestriels
More news
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | EW | US28176E1082 | MarketScreener
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 89,68 $
Last Close Price 85,76 $
Spread / Highest target 22,4%
Spread / Average Target 4,57%
Spread / Lowest Target -25,4%
EPS Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
John P. McGrath Vice President-Quality, Regulatory & Clinical
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
William J. Link Independent Director
Sector and Competitors